
SNTI Stock Forecast & Price Target
SNTI Analyst Ratings
Bulls say
Senti Biosciences has demonstrated a positive outlook primarily due to the promising preliminary results of its lead product candidate, SENTI-202, showing a 42% complete response rate in relapsed/refractory acute myeloid leukemia (AML) patients. The company’s recent designation of Regenerative Medicine Advanced Therapy (RMAT) for SENTI-202 is expected to facilitate strategic engagement with the FDA, potentially expediting the pathway towards pivotal trials set for initiation in 2026. Furthermore, the significant reductions in leukemic stem cells while preserving normal hematopoietic stem and progenitor cells enhances the therapeutic potential of Senti's innovative CAR-NK cell therapies, reinforcing investor confidence in the company's future prospects.
Bears say
Senti Biosciences Inc. is facing potential downward revisions in its price target and risk-adjusted projections due to uncertainties surrounding its clinical-stage product candidates and overall market performance. Concerns about the viability of its therapies, particularly the SENTI-202 and SENTI-301A, may lead to adjustments in fundamental financial metrics that impact investor sentiment. Additionally, the repetitive indication of potential downward revisions highlights significant risks associated with the company's strategic direction and market positioning in the competitive biotechnology landscape.
This aggregate rating is based on analysts' research of Senti Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.
SNTI Analyst Forecast & Price Prediction
Start investing in SNTI
Order type
Buy in
Order amount
Est. shares
0 shares